REVIEW ARTICLES
Platelets and restenosis
Baskaran Chandrasekar, MDa and
Jean-François Tanguay, MDa
a Division of Interventional Cardiology, Montreal Heart Institute, Montreal, Canada
Manuscript received June 4, 1999;
revised manuscript received September 26, 1999,
accepted November 15, 1999.
Reprint requests and correspondence: Dr. J F Tanguay, Montreal Heart Institute, 5000 Belanger, Montreal H1T 1C8, Canada
Tanguay{at}icm.umontreal.ca
Restenosis is currently the major limitation of percutaneous transluminal coronary angioplasty (PTCA). Factors such as elastic recoil, migration of vascular smooth muscle cells from media to intima, neointimal proliferation and vascular remodeling underly the restenotic process. Presently there is no effective therapy available for restenosis. The role of platelets in the development of thrombosis and abrupt closure after PTCA is well recognized. However, the effects of platelets in PTCA extend well beyond the early phase. Although antiplatelet agents such as glycoprotein IIb/IIIa antagonists have been reported to reduce target vessel revascularization, major unresolved controversies still exist. This report reviews the potential role of platelets in restenosis. Various drugs, successfully tested in experimental studies and in a small number of human studies, that inhibit the effect of platelets on the restenotic process are also reviewed.
|
Abbreviations and Acronyms
| | AS-OLN | = antisense oligonucleotides | | DNA | = deoxyribonucleic acid | | GP | = glycoprotein | | mRNA | = messenger ribonucleic acid | | PDGF | = platelet-derived growth factor | | PTCA | = percutaneous transluminal coronary angioplasty | | SMC | = smooth muscle cell | | TGF | = transforming growth factor |
|
This article has been cited by other articles:
|
|
|
|
 
V. G. Cin, H. Pekdemir, M. N. Akkus, A. Camsari, O. Doven, and S. Yenihan
Cutting Balloon Angioplasty for the Treatment of In-Stent Restenosis in Diabetics: A Matched Comparison of 6 Months' Outcome With Conventional Balloon Angioplasty
Angiology,
August 1, 2006;
57(4):
445 - 452.
[Abstract]
[PDF]
|
|
|
|
|
|
|
G. W. Stone and H. D. Aronow
Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy
Mayo Clin. Proc.,
May 1, 2006;
81(5):
641 - 652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Myler, E. A. Lipke, E. E. Rice, and J. L. West
Novel heparanase-inhibiting antibody reduces neointima formation.
J. Biochem.,
March 1, 2006;
139(3):
339 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Singh, B. J. Gersh, R. L. McClelland, K. K.L. Ho, J. T. Willerson, W. F. Penny, and D. R. Holmes Jr
Predictive factors for ischemic target vessel revascularization in the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial
J. Am. Coll. Cardiol.,
January 18, 2005;
45(2):
198 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Smout, D. P. Mikhailidis, B. K. Shenton, and G. Stansby
Combination Antiplatelet Therapy in Patients with Peripheral Vascular Bypass Grafts
Clinical and Applied Thrombosis/Hemostasis,
January 1, 2004;
10(1):
9 - 18.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Zhan, S. Kim, Y. Izumi, Y. Izumiya, T. Nakao, H. Miyazaki, and H. Iwao
Role of JNK, p38, and ERK in Platelet-Derived Growth Factor-Induced Vascular Proliferation, Migration, and Gene Expression
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2003;
23(5):
795 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip, M. S. Chauhan, D. S. Baim, K. K. L. Ho, J. J. Popma, J. P. Carrozza, D. J. Cohen, and R. E. Kuntz
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials
J. Am. Coll. Cardiol.,
December 18, 2002;
40(12):
2082 - 2089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Geraldes, M. G. Sirois, P. N. Bernatchez, and J.-F. Tanguay
Estrogen Regulation of Endothelial and Smooth Muscle Cell Migration and Proliferation: Role of p38 and p42/44 Mitogen-Activated Protein Kinase
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2002;
22(10):
1585 - 1590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ichii, H. Koyama, S. Tanaka, A. Shioi, Y. Okuno, S. Otani, and Y. Nishizawa
Thrombospondin-1 Mediates Smooth Muscle Cell Proliferation Induced by Interaction With Human Platelets
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2002;
22(8):
1286 - 1292.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wang, A. H. Campos, C. Z. Prince, Y. Mou, and M. J. Pollman
Coordinate Notch3-Hairy-related Transcription Factor Pathway Regulation in Response to Arterial Injury. MEDIATOR ROLE OF PLATELET-DERIVED GROWTH FACTOR AND ERK
J. Biol. Chem.,
June 21, 2002;
277(26):
23165 - 23171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Graff, U. Klinkhardt, V. B. Schini-Kerth, S. Harder, N. Franz, S. Bassus, and C. M. Kirchmaier
Close Relationship between the Platelet Activation Marker CD62 and the Granular Release of Platelet-Derived Growth Factor
J. Pharmacol. Exp. Ther.,
March 1, 2002;
300(3):
952 - 957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Konishi, Y. Katoh, N. Takaya, Y. Kashiwakura, S. Itoh, C. Ra, and H. Daida
Platelets Activated by Collagen Through Immunoreceptor Tyrosine-Based Activation Motif Play Pivotal Role in Initiation and Generation of Neointimal Hyperplasia After Vascular Injury
Circulation,
February 26, 2002;
105(8):
912 - 916.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Smyth, E. D. Reis, W. Zhang, J. T. Fallon, R. E. Gordon, and B. S. Coller
{beta}3-Integrin-Deficient Mice but Not P-Selectin-Deficient Mice Develop Intimal Hyperplasia After Vascular Injury : Correlation With Leukocyte Recruitment to Adherent Platelets 1 Hour After Injury
Circulation,
May 22, 2001;
103(20):
2501 - 2507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Steinhubl, S. G. Ellis, K. Wolski, A. M. Lincoff, and E. J. Topol
Ticlopidine Pretreatment Before Coronary Stenting Is Associated With Sustained Decrease in Adverse Cardiac Events : Data From the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
Circulation,
March 13, 2001;
103(10):
1403 - 1409.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
